Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingdi Kechuanning
- Development stage
- Phase 2
- Lead developer
- Simcere Pharmaceutical Group
- Administration
- Oral
01
Overview
Xingdi Kechuanning is a Traditional Chinese Medicine (TCM) formulation developed by Guizhou Weimen Pharmaceutical for the treatment of respiratory conditions including chronic obstructive pulmonary disease (COPD), acute exacerbations of chronic bronchitis, and asthma. Formulated as a capsule, it is specifically indicated for patients presenting with wind-cold binding the lung and kidney qi deficiency syndromes according to TCM principles. The therapy aims to relieve cough and wheezing by harmonizing lung and kidney functions. It has been evaluated in Phase II clinical trials in China.
- Brand names
- Xingdi Kechuanning
- Other names
- Xingdi Kechuanning Capsule杏蒂咳喘宁
Beyond the preview
Go deeper on Xingdi Kechuanning.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xingdi Kechuanning.